Support for people recovering from opioid overdoses in Seattle
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
This study tests a new support center for people recovering from opioid overdoses in Seattle to see if it helps them get better care and stay safe compared to those who don’t use the center.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Washington Academic / other |
| Locations | 1 site (Seattle, Washington) |
| Trial ID | NCT06768814 on ClinicalTrials.gov |
What this trial studies
This study investigates a new sub-acute stabilization center (SASC) designed for individuals who have experienced or are at risk of opioid overdoses. Participants will be referred by Seattle Fire Department emergency medical services and will receive comprehensive care, including monitoring, medication-assisted treatment, and linkage to ongoing support services. The study will compare outcomes for those who utilize the SASC with those who do not, using data from EMS records and stakeholder interviews to assess implementation and effectiveness.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have experienced or are at high risk for opioid overdose and are willing to consent to transfer of care to the SASC.
Not a fit: Patients who are not experiencing an opioid overdose or do not meet the clinical inclusion criteria will not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could significantly improve recovery outcomes and access to care for individuals affected by opioid use disorder.
How similar studies have performed: Other studies have shown promise in similar approaches to overdose recovery and harm reduction, indicating potential for success in this intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Verbally consents to transfer of care to SASC. 2. Awake and oriented to person and place, with no significant deficits in mental status or neurological function. 3. Age \>=18 4. Patent airway and effective respirations with adequate oxygenation. 5. Stable heart rate and blood pressure, with no evidence of cardiac arrhythmias or other significant cardiovascular disfunction. 6. Vitals: * Heart rate: 45-130 * Blood pressure: systolic 95-190, diastolic 50-120 * Respiratory rate: 10-24 * SpO2: \>92 on room air or supplemental O2 via nasal cannula. * SpO2 \<92% with supplemental O2 requires ED transfer. * EtCO2: \<50 * Temperature: 95.5-100.3 F * Blood glucose (if indicated): 60-300 7. No signs of head trauma: * Dizziness or loss of balance * Blurred vision or double vision * Sensitivity to light or noise * Seizures or convulsions * Weakness or numbness in the arms or legs * Persistent or worsening headache * CSF or blood leaking from the nose or ears * Unequal pupils or pupils that are slow to react to light. 8. No signs of other traumatic injury or medical needs requiring immediate treatment. 9. No signs of respiratory infection. Screen for COVID-19. See COVID-19 Screening protocol. Exclusion Criteria: \- People under 18 and who do not meet SASC admission criteria will be excluded.
Where this trial is running
Seattle, Washington
- Downtown Emergency Service Center's Overdose Recovery and Care Access Centers — Seattle, Washington, United States (Recruiting)
Study contacts
- Principal investigator: Caleb Banta-Green, PhD, MPH, MSW — University of Washington
- Study coordinator: Anthony S Floyd, PhD
- Email: asfloyd@uw.edu
- Phone: 206-616-7382
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.